ID: ALA2325075

Max Phase: Preclinical

Molecular Formula: C21H25ClF3N3O3

Molecular Weight: 459.90

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(N[C@H]1CCC[C@H](CO)C1)C1CCN(c2nc3cc(Cl)c(C(F)(F)F)cc3o2)CC1

Standard InChI:  InChI=1S/C21H25ClF3N3O3/c22-16-10-17-18(9-15(16)21(23,24)25)31-20(27-17)28-6-4-13(5-7-28)19(30)26-14-3-1-2-12(8-14)11-29/h9-10,12-14,29H,1-8,11H2,(H,26,30)/t12-,14-/m0/s1

Standard InChI Key:  XBOPOFUFNFYKFG-JSGCOSHPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 459.90

Molecular Weight (Monoisotopic): 459.1537

AlogP: 4.38

#Rotatable Bonds: 4

Polar Surface Area: 78.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.31

CX LogP: 3.81

CX LogD: 3.81

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.71

Np Likeness Score: -1.19

References

1. Walker DP, Arhancet GB, Lu HF, Heasley SE, Metz S, Kablaoui NM, Franco FM, Hanau CE, Scholten JA, Springer JR, Fobian YM, Carter JS, Xing L, Yang S, Shaffer AF, Jerome GM, Baratta MT, Moore WM, Vazquez ML..  (2013)  Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design.,  23  (4): [PMID:23298810] [10.1016/j.bmcl.2012.11.107]

2. Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML..  (2013)  Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.,  23  (4): [PMID:23260349] [10.1016/j.bmcl.2012.11.109]

Source

Source(1):

• Scientific Literature